title: The monitoring of antiaggregation effect of acetylsalicylic acid therapy by measuring serum thromboxane B2 in patients with coronary artery bypass grafting.
abstract: Cardiovascular patients take acetylsalicylic acid (ASA) for preventing myocardial infarction and other thromboembolic complications. It is already known that in some patients this therapy is not effective. The aim of this study was to assess the percentage of ASA resistance on the sample of patients with coronary artery bypass grafting. Our study included 105 patients with coronary artery bypass grafting treated with ASA 150 mg/day or lesser. Platelet aggregation was measured by serum thromboxane B2 level as well as impedance aggregometry from whole blood to determine ASA antiaggregation effect. The percentage of ASA resistance was 41.9% with impedance aggregometry, and after determining the serum thromboxane B2 level this percentage was only 8.6%. The correlation between these two methods was weak (r = 0.443; P < 0.0001). Thromboembolic complications still occur in ASA-treated patients because some patients are resistant to ASA therapy. It would be useful to monitor the effectiveness of ASA therapy and give another antiaggregation drug to these patients to reduce adverse events. The problem is which test is ideal because different tests show different percentages of ASA resistance.
authors.affiliation: aMedical Biochemistry Laboratory, Special Hospital for Medical Rehabilitation Krapinske, Toplice, Krapinske ToplicebDepartment of Cardiology, Special Hospital for Medical Rehabilitation Krapinske Toplice, Faculty of Medicine Osijek, J. J. Strossmayer University of Osijek, Osijek, Croatiac2nd Department of Internal Medicine, Comenius University and University Hospital, Bratislava, SlovakiadInternational Clinical Research Center, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic*Ludovit Gaspar and Peter Kruzliak contributed equally to the writing of this article.
authors.forename: Anita
authors.initials: A
authors.lastname: Klasic
authors.forename: Nenad
authors.initials: N
authors.lastname: Lakusic
authors.forename: Ludovit
authors.initials: L
authors.lastname: Gaspar
authors.forename: Peter
authors.initials: P
authors.lastname: Kruzliak
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects*; D016022:Case-Control Studies; D001026:Coronary Artery Bypass; D003324:Coronary Artery Disease / Q000097:blood* / Q000473:pathology / Q000601:surgery; D004334:Drug Administration Schedule; D016903:Drug Monitoring / Q000295:instrumentation / Q000379:methods*; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010979:Platelet Function Tests; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; D001241:Aspirin